JP2010519192A - 瘢痕の抑制のためのｗｎｔ３ａ - Google Patents

瘢痕の抑制のためのｗｎｔ３ａ Download PDF

Info

Publication number
JP2010519192A
JP2010519192A JP2009549467A JP2009549467A JP2010519192A JP 2010519192 A JP2010519192 A JP 2010519192A JP 2009549467 A JP2009549467 A JP 2009549467A JP 2009549467 A JP2009549467 A JP 2009549467A JP 2010519192 A JP2010519192 A JP 2010519192A
Authority
JP
Japan
Prior art keywords
wnt3a
derivative
therapeutically effective
scars
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009549467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519192A5 (enExample
Inventor
ウイリアム ジェイムズ ファーガソン マーク
ラベルティ ヒュー
オクレストン ニコラス
オケイン シャロン
ニールド ケリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of JP2010519192A publication Critical patent/JP2010519192A/ja
Publication of JP2010519192A5 publication Critical patent/JP2010519192A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009549467A 2007-02-15 2008-02-14 瘢痕の抑制のためのｗｎｔ３ａ Withdrawn JP2010519192A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0702930.9A GB0702930D0 (en) 2007-02-15 2007-02-15 Medicaments and methods for inhibition of scarring
PCT/GB2008/000500 WO2008099174A1 (en) 2007-02-15 2008-02-14 Wnt3a for inhibition of scarring

Publications (2)

Publication Number Publication Date
JP2010519192A true JP2010519192A (ja) 2010-06-03
JP2010519192A5 JP2010519192A5 (enExample) 2011-03-31

Family

ID=37908674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549467A Withdrawn JP2010519192A (ja) 2007-02-15 2008-02-14 瘢痕の抑制のためのｗｎｔ３ａ

Country Status (7)

Country Link
US (1) US20110212897A1 (enExample)
EP (1) EP2117581A1 (enExample)
JP (1) JP2010519192A (enExample)
AU (1) AU2008216004A1 (enExample)
CA (1) CA2678389A1 (enExample)
GB (1) GB0702930D0 (enExample)
WO (1) WO2008099174A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029061A (ja) * 2011-08-04 2016-03-03 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9581723B2 (en) 2008-04-10 2017-02-28 Schlumberger Technology Corporation Method for characterizing a geological formation traversed by a borehole
US8725477B2 (en) 2008-04-10 2014-05-13 Schlumberger Technology Corporation Method to generate numerical pseudocores using borehole images, digital rock samples, and multi-point statistics
ES2341419B1 (es) * 2008-08-14 2011-05-03 Hospital Clinic I Provincial De Barcelona Wnt1 como biomarcador de daño renal.
EP2226080A1 (en) * 2009-03-05 2010-09-08 Universiteit Maastricht Antagonistic peptides for frizzled-1 and frizzled-2
US8311788B2 (en) 2009-07-01 2012-11-13 Schlumberger Technology Corporation Method to quantify discrete pore shapes, volumes, and surface areas using confocal profilometry

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1737948A2 (en) * 2004-04-16 2007-01-03 Hydra Biosciences, Inc. Methods of promoting cardiac cell proliferation
EP1844787A4 (en) * 2005-01-18 2011-10-19 Univ Kyoto DRUGS FOR NERVE CELL REGENERATION
GB0613031D0 (en) * 2006-06-30 2006-08-09 Renovo Ltd Medicaments

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016029061A (ja) * 2011-08-04 2016-03-03 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途
JP2017008030A (ja) * 2011-08-04 2017-01-12 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途

Also Published As

Publication number Publication date
EP2117581A1 (en) 2009-11-18
AU2008216004A1 (en) 2008-08-21
CA2678389A1 (en) 2008-08-21
GB0702930D0 (en) 2007-03-28
WO2008099174A1 (en) 2008-08-21
US20110212897A1 (en) 2011-09-01

Similar Documents

Publication Publication Date Title
US20100266532A1 (en) Methods for inhibiting scarring
JP2012211185A (ja) 創傷治癒のためのｉｌ−１０関連ペプチド
WO2008078099A1 (en) Lxr- antagonists for the prevention, reduction or inhibition of scarring
JP2010519192A (ja) 瘢痕の抑制のためのｗｎｔ３ａ
US20100144690A1 (en) Medicaments and methods for promoting wound contraction
JP2010524910A (ja) 瘢痕の抑制に使用できる分泌性Ｆｒｉｚｚｌｅｄ関連タンパク質
JP2009542609A (ja) 薬剤
JP2011522020A (ja) 瘢痕を抑制する薬剤および方法
JP2010535184A (ja) 非眼瘢痕の抑制に使用できる薬剤および方法
CA2733797A1 (en) Methods for inhibition of scarring
US20110152189A1 (en) Methods for the inhibition of scarring
WO2010063994A1 (en) Non-surgical improvement of scars
US20100286055A1 (en) Use of wnt3a for acceleration of wound healing
HK1105366B (en) Il-10 related peptides for wound healing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110207

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110207

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120927